Introduction
Peripheral artery disease (PAD) is a widely occurring condition. The main cause is atherosclerosis, and the causes of atherosclerosis constitute the predisposing factors for the disease (1) .
Atherosclerosis, the cause of PAD, is generally a condition of advanced age. It develops in association with intimal plaques affecting arterial circulation of the vascular system and containing varying proportions of lipids, macrophages, fibroblasts, smooth muscle cells, and extracellular materials. Atherosclerosis is also a chronic inflammatory condition (2) .
Pentraxins (PTX) are multifunctional protein superfamily that play a role in the inflammatory response. PTX3 is one of the main acute phase reactants, which may increase in circulation 3-5 times above the baseline in inflammatory conditions. PTX3 is produced in the region of inflammation and binds immediately to the endothelium. PTX3 levels are believed to be an independent marker of disease activity (3) .
Since a chronic inflammatory process is involved in atherosclerosis, PTX3 is an inflammatory marker that might be expected to increase in PAD. This study investigated whether PTX3 increases in patients with PAD.
Materials and Methods
Patients with suspected PAD based on symptoms at presentation to the tertiary university hospital emergency department and cardiovascular surgery departments over a 12-month period were included in this cross-sectional clinical study after receiving of approval from the local ethics committee. The study enrolled 43 consecutive adult patients presenting to the aforementioned units with suspected PAD and 40 age-and sex-matched healthy controls contacted from outside the hospital.
Patients aged ≥18 years presenting to the departments with suspected PAD and agreeing to participate were included. Exclusion criteria were patients with acute coronary syndrome, acute kidney failure, chronic kidney failure, hemorrhagic stroke, cerebrovascular disease, liver failure, acute pulmonary edema, cardiopulmonary arrest, acute mesenteric ischemia, or pulmonary thromboembolism.
Clinical and demographic characteristics, such as symptoms, physical examination findings and Doppler ultrasound, peripheral arterial with contrast computerized tomography, and magnetic resonance angiography details were recorded into a study form.
The control group inclusion criteria included non-pregnant or puerperant patients, aged ≥18 years with no acute kidney failure, chronic kidney failure, sepsis, ischemic stroke, liver failure, acute pulmonary edema, PAD, deep vein thrombosis, acute coronary syndrome, pulmonary embolism, mesenteric ischemia, cardiopulmonary arrest, multi-trauma, Tissue Plasminogen Activator (TPA)-related hemorrhage or acute trauma.
For PTX3 measurements at the time of presentation, a complete blood count (CBC) was performed by collecting blood samples in the anticoagulant ethylenediaminetetraacetic acid (EDTA) tubes. Plasma was separated by centrifugation at 1800× g for 10 min and then stored at −80°C until PTX3 study.
Measurement of plasma pentraxin-3
PTX-3 levels in human plasma were determined using a commercial enzyme-linked immuno-sorbent assay (ELISA) kit (R&D Systems, Cat No: DPTX30, Minneapolis, USA) following the manufacturer's instructions. Plasma stored at −80°C was thawed to room temperature.
Briefly, 200 µL of PTX3 biotinylated antibody was added into each well of a streptavidin-coated plate. Plates were incubated for 60 min at room temperature on a microplate shaker. The plates were subsequently washed using 300 µL washing buffer to remove nonbinding antibodies. PTX3 standards were prepared in line with the kit procedures. Standards, controls, and specimens were activated with pre-treatment D solution for 30 min. Further, 100 µL assay diluent solution was added to each plate; 20 µL of pre-treated standards, controls, and specimens were added to the solution and incubated for 120 min in a microplate shaker at room temperature. Following incubation, the plate was washed four times with washing buffer in a plate washer; 200 µL of PTX3 conjugate was added into the wells and incubated at room temperature for 120 min on a microplate shaker. Following incubation, the plate was washed four times using washing buffer in a plate washer. Subsequently, 200 µL of Tetra Metil Benzidin (TMB) substrate solution was added to each well for color development and incubated in dark for 30 min at room temperature; 50 µL of color stop solution was added to each well, and specimens were observed to turn yellow in color. Absorbance was measured at a wavelength of 450 nm using a microplate reader (Versamax, Molecular Devices, CA, USA). A standard chart was prepared using the absorbance values against standard concentrations obtained. PTX3 levels in specimens were calculated as ng/mL using this standard chart. The intra-assay distribution reliability of this ELISA method was 3.6% and the inter-assay distribution reliability was 4.9%.
Statistical analysis
Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS Inc.; Chicago, IL, USA) version 11 software. The normality of the distribution of variables was tested using visual (histogram and probability charts) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk tests). Descriptive analyses were expressed as mean and standard deviation for normally distributed variables. These were compared on 2×2 grids using Person's chi square and Fisher's exact tests. Since PTX3 and ankle brachial index (ABI) values were not normally distributed, these were analyzed using the Mann-Whitney U test between two groups and with the KruskalWallis test between more than two groups. Spearman's correlation test was used to investigate correlations. P values less than 0.05 were regarded as statistically significant.
Results
The mean age of the participants was 63.9±11.9 years (min: 40, max: 86) in the control group and 64.5±13.8 years (min: 21, max: 88) in the patient group. Males comprised 67.5% of the control group and 81.4% of the patient group. No significant difference was observed between the two groups in terms of age or gender distribution (p>0.05; Table 1 ).
When physical examination findings were compared between the control and patient groups, no ulcer, muscular atrophy, claudication, rash, or edema were observed in the control group; however, ulcer was present in 41.9%, muscular atrophy in 9.3%, claudication in 100%, rash in 53.5%, and edema in 44.2% of the patient group (p<0.001 except for muscular atrophy; Table 1 ). When patients were questioned about comorbidities other than PAD, coronary artery disease (CAD) was present in 45% of the control group and 53.5% of the patient group, hypertension (HT) in 60% of the control group and 67.4% of the patient group, hyperlipidemia (HPL) in 25% of the control group and 23.3% of the patient group, and diabetes mellitus (DM) in 35.0% of the control group and 53.5% of the patient group. No significant correlation was determined between the groups in terms of CAD, HT, HPL, or DM (p>0.05; Table 1 ).
When participants' electrocardiography (ECG) findings were compared, normal ECG results were determined in almost all in the control group, while atrial fibrillation (AF) was determined in 14% of the patient group, atrial flutter (AFL) in 2.3%, non-ST changes in 2.3%, and ischemic ST elevation in 25.6% (Table 1) .
Median PTX3 level in the control group was 1.027 ng/mL (25-75 A weak and insignificant correlation was observed when we compared ABI values currently used as a diagnostic test with the new method PTX3 (r=0.016; p=0.886; Figure 3) . PTX3 values investigated as a novel method also exhibited no significant correlation with any other measurement parameters (age, systolic BP, diastolic BP, heart rate, respiration rate, temperature, and SpO 2 ) (p>0.05).
Examination of the relations between PTX3 and sociodemographic variables, physical examination, and additional chronic diseases showed that none was a probable confounding factor. Accordingly, no correlation was determined between age, muscle atrophy, claudication, rash, edema, CAD, HT, HPL, DM, or smoking status and PTX3 values (p>0.05). Studies have reported varying prevalence of PAD. The prevalence of PAD in the general population aged over 40 years in Spain was reported as 9.7% in women and 11.4% in men (4) . A prevalence level of 5% for PAD (ABI <0.9) has been reported in individuals representing the general population aged ≥40 years in the USA (5) . A study conducted in a care home in Turkey involving 507 individuals aged >60 years reported a prevalence of PAD of 5.9%, while a study that screened the general population aged >40 years reported a prevalence of 19.76% (6) .
Discussion
Various studies have been performed for the early identification of PAD (7). However, the application of PTX3, an inflammatory marker, in the diagnosis of PAD has not been previously investigated. As described, PTX3 plays an important role in the primary inflammatory response. It is therefore included among the diagnostic tests for several diseases and cardiovascular diseases (CVDs) in particular, from ovarian torsion to pleural fluid effusion and pulmonary contusion (8, 9) . Immunohistochemical studies have shown that plasma PTX3 levels increase in atherosclerotic lesions but not in non-atherosclerotic lesions and have demonstrated that PTX3 is a marker of localized vascular inflammation. This has emphasized the importance of investigating the relation between clinical atherosclerotic events and PTX3 levels. Additionally, the determination of higher PTX3 levels in subjects with CVD compared to those without CVD among patients with myocardial infarction with systolic BP elevation has led to PTX3 levels also being investigated in this group (10). Zhou et al. (11) reported a negative, highly significant correlation between PTX3 and ABI values. In our study, PTX3 and ABI did not correlate to age, systolic BP, diastolic BP, heart rate, respiration rate, body temperature, or SpO 2 . Although Tomandlova et al. (10) referred to a significant correlation between age and PTX3, they reported no correlation between systolic or diastolic BP and PTX3, in agreement with our study. In a study investigating the relation between severity of PAD and endothelial progenitor cells (EPCs), Morishita et al. (12) reported that EPCs and PTX3 increased in a correlated manner in patients with PAD compared to those without PAD. In our study, and in contrast to Morishita et al. (12) , PTX3 levels were lower in subjects with PAD, although the difference was not statistically significant. In addition, Morishita et al. (12) reported a 33.3% prevalence of DM, 71.4% of HT, and 38.1% of CVD among subjects with PAD. In our study, the prevalence values in patients with PAD were 53.5% for DM, 67.4% for HT, and 53.5% for CVD, indicating higher prevalence of DM and CVD but not HT. Additionally, mean systolic (137.38±26.20 mmHg) and diastolic (73.81±14.74 mmHg) BP values in the study by Morishita et al. (12) were similar to those of our study (systolic: 128.23±18.59 mmHg; diastolic: 77.58±12.55 mmHg). Inoue et al. (13) compared mean plasma PTX3 levels by collecting blood specimens from 252 patients undergoing angiography for CAD evaluation at a university hospital, with 162 patients under monitoring due to HT, HPL, DM, or CVD. Mean PTX-3 values of patients undergoing angiography with a preliminary diagnosis of ischemic heart disease were significantly high. In the study of patients with type 2 DM, Rashtchizadeh et al. (14) observed significantly higher mean PTX3 in patients with CAD compared to those with no CAD. However, no such relationship was observed in our study.
Studies regarding PTX3 have revealed that the levels of PTX3 also increase in some inflammatory diseases. In a study of patients with arthritis, Ishihara et al. (15) observed higher serum PTX3 levels in periods when the disease was active compared to when it was not active and compared to a healthy control group. They reported patients with vasculitis. They observed higher PTX3 levels in active vasculitis compared to during times of no activation. Moreover, PTX3 levels when the disease was not activated and in the healthy control group was similar. The study also observed high PTX3 levels in an untreated vasculitis group and low levels in subjects receiving immunosuppressive therapy. They concluded that PTX3 may be a reliable acute phase reactant in showing inflammation in active vasculitis (3) . Studies investigating risk factors for PAD have identified DM, HL, HT, smoking, and obesity as such factors (16) . More than 91% of patients with PAD were reported to have at least one risk factor for atherosclerosis (4) . Similarly, in our study, 94% of patients had at least one such risk factor.
Several previously published studies have reported that coronary problems are encountered frequently in patients with PAD. In addition, one necroscopy study involving cases with lower extremity ischemia sufficiently severe to require amputation observed diffuse and severe coronary atherosclerotic and myocardial lesions in almost all these cases (17) . CAD was diagnosed in 23 (53.5%) of the PAD cases in this study. A history of non-ST elevation was present in 1 (2.3%) patient and ischemic ST elevation in 11 (25.6%). In addition, median value of ABI of 1.15 (25-75 th percentiles: 1.10-1.20) in the control group was significantly higher than median value of ABI 0.51 (25-75 th percentiles: 0.36-0.66) in the subjects with PAD (p<0.001), indicating that consistent results were obtained in the diagnosis of PAD.
Study limitations
The absence of any significant finding in this study despite PTX3 being closely associated with atherosclerosis and the fact that the result did not change despite the grading of confounding factors, show the need for a larger and randomized sample.
Conclusion
We consider that PTX3 levels remained unchanged in this study because despite its atherosclerotic foundation, PAD is a chronic process that does not develop acutely. Further studies with a larger patient group and with PAD classified according to subtypes are needed. 
